安必平(688393) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was CNY 347.27 million, a decrease of 26.24% compared to the previous year[3] - Net profit attributable to shareholders was CNY -44.97 million, a decline of 311.22% year-on-year[3] - The company reported a net profit of CNY -65.90 million after deducting non-recurring gains and losses, a decrease of 562.30% compared to the previous year[3] - Basic earnings per share were CNY -0.48, down 308.70% from CNY 0.23 in the previous year[3] Assets and Equity - Total assets at the end of the reporting period were CNY 1,290.87 million, a decrease of 5.27% from the beginning of the period[5] - Shareholders' equity attributable to the parent company was CNY 1,190.04 million, down 5.23% from the beginning of the period[5] Revenue Impact Factors - The decline in revenue was significantly impacted by the national centralized procurement policy, leading to a revenue drop of approximately CNY 46.50 million from the HPV product line[6] - The company is focusing on optimizing its business structure and expanding distribution channels, which has temporarily affected overall gross margins[6] Future Outlook - Increased operational costs due to ongoing product research and development efforts in the fields of digital pathology and tumor companion diagnostics are expected to support long-term sustainable growth[6] - Investors are advised to note that the financial data presented is preliminary and unaudited, with final figures to be confirmed in the audited annual report[8]